- Letter to the Editor
- Open Access
LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1
Molecular Cancer volume 17, Article number: 127 (2018)
The long noncoding RNA ANRIL has been found to be abnormally expressed and play important roles in different cancers. However, the expression and function of ANRIL in acute myeloid leukemia (AML) remain to be declared. In this study, we found that ANRIL is up-regulated in AML patients at diagnosis and down-regulated in patients after complete remission (CR). Functional studies showed that knockdown of ANRIL expression resulted in a decline in glucose uptake and inhibition of AML cell maintenance in vitro and in vivo. Mechanically, ANRIL was found to repress the expression of Adiponectin receptor (AdipoR1), a key regulator of glucose metabolism. Both ANRIL and AdipoR1 knockdown reduced the expression levels of phosphorylation of AMPK and SIRT1, implying a previously unappreciated ANRIL-AdipoR1-AMPK/SIRT1 signaling pathway in regulating cell glucose metabolism and survival in AML. The study is the first to demonstrate that ANRIL promotes malignant cell survival and cell glucose metabolism to accelerate AML progression and is a potential prognostic marker and therapeutic target in AML treatment.
AML is a heterogeneous malignancy characterized by uncontrollable proliferation of leukemia cells in bone marrow, and accounts for 30% of leukemia-related pediatric deaths [1, 2]. Despite recent progress in treating AML, its long-term survival is still poor due to the development of resistance and the high rates of relapse after treatment with the currently available chemotherapy [1, 2]. Thus, finding novel therapy targets is urgently needed to improve the clinical outcomes of AML.
In recent years, long non-coding RNAs (lncRNAs) have been found to be dysregulated in cancer [3,4,5]. However, lncRNAs that regulate AML development and progression remain largely unstudied. In our previous study, we noted that an lncRNA, ANRIL (antisense non-coding RNA at the INK4 locus), was highly expressed in acute leukemia patients compared to that in normal controls . ANRIL was reported to repress the expression of p15INK4B and p16INK4A in multiple solid tumors [3, 7]. More interestingly, ANRIL was recently found to transcriptionally suppress AdipoR1 in atherosclerosis and periodontitis . AdipoR1 is a key protein that is intimately involved with cell senescence and metabolism [7, 8]. Therefore, we hypothesized that ANRIL is involved in AML progression via regulating cell metabolism pathways.
Results and discussion
ANRIL is significantly higher expressed in patient samples and regulates cell survival in AML
To validate the expression pattern of ANRIL in AML, we recruited 109 with newly diagnosed AML and 14 controls to evaluate the clinical relevance of ANRIL. The detailed clinical parameters are presented in Additional file 1: Table S1. As shown in Fig. 1a, the expression level of ANRIL was remarkably increased in AML patients in different stages of AML compared with normal controls, and significantly decreased in CR patients (Fig. 1a and Additional file 1: Figure S1a), suggesting that ANRIL might function as an oncogene in AML.
To demonstrate the oncogenic role of ANRIL, we applied RNA interference (RNAi) to knock down the expression of ANRIL in AML cell lines HL-60 and MOLM-13 (Additional file 1: Figure S1b) and investigated the effects of ANRIL on cell functions. As shown in Fig. 1b and Additional file 1: Figure S1c, senescence cells stained with SA-β-gal were increased after ANRIL knockdown, indicating that down-regulation of ANRIL was able to promote cell senescence. Similarly, the repression of ANRIL resulted in a remarkable decrease in AML cell growth compared with the negative control (Fig. 1c and Additional file 1: Figure S1d). In addition, we also detected the impact of ANRIL on apoptosis induced by ATO (arsenic trioxide), a chemotherapeutic drug in AML treatment, and found that knockdown of ANRIL facilitated ATO-induced cell apoptosis in a time course (24 h, 48 h, 72 h) in AML cells (Fig. 1d and Additional file 1: Figure S1e). We also detected two major apoptosis-related factors, caspase-3 and PARP, and found the cleaved PARP and caspase 3 were significantly increased/decreased upon knockdown/overexpression of ANRIL, respectively (Fig. 1e, f and Additional file 1: Figure S1f, g). Together, these data indicated that ANRIL indeed functions as an oncogene in AML and could regulate leukemic cell survival.
ANRIL promotes AML progression in vivo
Next, a mouse model was used to further validate the function of ANRIL in vivo. MOLM-13 cells transfected with ANRIL short hairpin RNA (named as sh-ANRIL) and negative control short hairpin RNA (named as sh-NC) were intravenously (tail vein) implanted into NOD/SCID mice. The knockdown efficiency was shown in Additional file 1: Figure S2a. We killed the mice after 3 weeks and found that the percentages of GFP+ MOLM-13 cells in BM, peripheral blood and spleen were significantly lower in the ANRIL-knockdown mice than that in sh-NC mice (Fig. 1g and Additional file 1: Figure S2b). Furthermore, bone marrow smear results also showed that the amount of GFP+ MOLM-13 cells from sh-ANRIL group decreased after transplantation (Fig. 1h). Notably, the sh-ANRIL groups survived longer than the control groups (Fig. 1i), suggesting that ANRIL-knockdown could inhibit AML maintenance.
ANRIL affects a number of genes involved in AML cell metabolism pathways
We then investigated the underlying mechanism for ANRIL-mediated regulation of AML progression. Using the RNA-seq approaches, we analyzed and compared the expression pattern of mRNAs from the MOLM-13 cells tranfected with sh-ANRIL and sh-NC, and found a set of mRNAs expressed abnormally in sh-ANRIL MOLM-13 cells compared with sh-NC cells (Additional file 1: Figure S3). The Fig. 2a showed the most differentially expressed ones (fold-change> 2.0) between sh-ANRIL and sh-NC, which include 60 mRNAs significantly up-regulated and 228 mRNAs significantly down-regulated in sh-ANRIL MOLM-13 cells. We used GO analysis to annotate biological process and clustered the modules of genes. Notably, as shown in the top 40 cluster ranked by p value, the “Metabolic process” (Marked in red) and “cell death regulation” (Marked in blue) were significantly enriched (Fig. 2b), suggesting that the lncRNA ANRIL might regulate the AML cell survival through modulating the leukemic cell metabolism.
ANRIL regulates AdipoR1 to trigger cell survival in AML
Among the down-regulated genes affected by ANRIL shown in Fig. 2a, AdipoR1 attracted our interesting. AdipoR1 was found to be transcriptionally suppressed by ANRIL in atherosclerosis, periodontitis . Thus, we asked if ANRIL regulated AML cell survival by targeting AdipoR1. We first detected the expression of AdipoR1 in AML patient samples, and found that the expression of AdipoR1 was significantly up-regulated in AML patients compared with that in normal controls, and down-regulated in patients who have achieved CR (Fig. 2c). The expression of AdipoR1 was positively correlated with ANRIL levels (Fig. 2d).The knockdown or overexpression of ANRIL resulted in the down- or up-regulation of AdipoR1 protein level (Fig. 2e and Additional file 1: Figure S4a), suggesting an association between ANRIL and AdipoR1 in AML. Silence of AdipoR1 expression could promote cell senescence, apoptosis, and decreased cell proliferation, which are similar to the effects of ANRIL (Fig. 2f-h and Additional file 1: Figure S4b-g). These data together demonstrated that ANRIL regulates the expression of AdipoR1 in AML.
ANRIL regulates cell survival through a glucose metabolism pathway of AdipoR1/AMPK/SIRT1
AdipoR1 has been demonstrated as a regulator in cell metabolism, such as Warburg effect that plays a pivotal role in cancer [7,8,9]. Therefore, we further investigated whether ANRIL enhances AML progression by regulating cell metabolism. As shown in Fig. 3a, knocking down both ANRIL and AdiopR1 resulted in a decline in glucose uptake in AML cells. Additionally, the levels of lactate in the culture medium declined after transfection of siRNA against ANRIL or AdipoR1 in AML cells (Fig. 3b), showing that both ANRIL and AdipoR1 are involved in the glucose metabolism of AML. To further confirm the regulation of ANRIL and AdipoR1 in glucose metabolism, we subsequently detected the expression of glucose transporter 1 (GLUT1), a glucose transporter that mediates the transportation of glucose across the plasma membrane of cells, and lactate dehydrogenase A (LDHA), a key enzyme that catalyzes the last step of glycolysis to convert pyruvate to lactate . These results showed that the expression of GLUT1 and LDHA decreased significantly upon knockdown of ANRIL (Fig. 3c) and AdipoR1 in AML cells (Fig. 3d). We next explored the cell glucose metabolism pathways that ANRIL might be involved in. AMPK and SIRT1, regulated by AdipoR1, are crucial targets in AML treatment and the main regulators of cell senescence and cell metabolism [8,9,10]. The expression of pAMPK (Thr172), the activated form of AMPK, and SIRT1 were concurrently decreased in AML cells once ANRIL and AdipoR1 were knocked down (Fig. 3e, f and Additional file 1: Figure S5a, b). Furthermore, the expression levels of pAMPK, SIRT1, GLUT1 and LDHA were increased when forced expression of ANRIL in AML cells (Fig. 3g). Finally, immunohistochemistry assay showed decreases of the ADIPOR1, pAMPKa and SIRT1 protein levels in the BM of the sh-ANRIL-Molm13 mice compared to those in the sh-NC-Molm13 control mice (Additional file 1:Figure S5c). These results illustrated that ANRIL could function as an oncogene in AML and regulate cell survival through a glucose metabolism signaling pathways of AdipoR1/AMPK/SIRT1 as shown in Fig. 3h.
ANRIL was found to be aberrantly expressed in AML patients and regulates the disease development through modulating the glucose metabolism pathway. As summarized in Fig. 3h, the function of ANRIL is realized by regulating a key regulator of glucose metabolism named AdipoR1 and its downstream factors AMPK/SIRT1 in AML. The study suggests that the specific expression pattern of ANRIL could serve as a promising target for AML diagnosis and treatment.
Adiponectin receptor 1
Acute lymphoblastic leukemia
Acute myeloid leukemia
Antisense non-coding RNA in the INK4 locus
Glucose transporter 1
Lactate dehydrogenase A
Long noncoding RNA
Quantitative real-time PCR
Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–52.
Quintana J, Advis P, Becker A, Beresi V, Campbell M, Vines EF, Garcia H, Salgado C, Vargas L, Rojas J, et al. Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results. Leukemia. 2005;19(12):2143–6.
Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43.
Qi F, Liu X, Wu H, Yu X, Wei C, Huang X, Ji G, Nie F, Wang K. Long noncoding AGAP2-AS1 is activated by SP1 and promotes cell proliferation and invasion in gastric cancer. J Hematol Oncol. 2017;10(1):48.
Wang WT, Ye H, Wei PP, Han BW, He B, Chen ZH, Chen YQ. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. J Hematol Oncol. 2016;9(1):117.
Fang K, Han BW, Chen ZH, Lin KY, Zeng CW, Li XJ, Li JH, Luo XQ, Chen YQ. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target. Hum Mol Genet. 2014;23(12):3278–88.
Bochenek G, Hasler R, El MN, Konig IR, Loos BG, Jepsen S, Rosenstiel P, Schreiber S, Schaefer AS. The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. Hum Mol Genet. 2013;22(22):4516–27.
Zha D, Wu X, Gao P. Adiponectin and its receptors in diabetic kidney disease: molecular mechanisms and clinical potential. Endocrinology. 2017;158(7):2022–34.
Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y, Zhang S, Gong Z, Wei F, Yang L, et al. Role of long non-coding RNAs in glucose metabolism in cancer. Mol Cancer. 2017;16(1):130.
Guo YN, Wang JC, Cai GY, Hu X, Cui SY, Lv Y, Yin Z, Fu B, Hong Q, Chen XM. AMPK-mediated downregulation of connexin43 and premature senescence of mesangial cells under high-glucose conditions. Exp Gerontol. 2014;51:71–81.
This research was supported by National Key R&D Program of China (No. 2017YFA0504400) and National Natural Science Foundation of China (No. 81770174 and 31870818), and grants from China Postdoctoral Science Foundation (Grant No. 2017 M610565 and 2017 T100653).
Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.
Ethics approval and consent to participate
Patients with AML and negative controls were obtained with informed consent from the First Affiliated Hospital of Sun Yat-sen University. Sample collection was approved by the the ethics committee of the affiliated hospitals of Sun Yat-sen University.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure S1. ANRIL regulates AML progression in vitro. Figure S2. ANRIL affects AML progression in vivo. Figure S3. Volcano plot based on differential mRNA profiles between sh-NC and sh-ANRIL established MOLM-13 cells. Figure S4. ANRIL regulates AML progression in vitro. Figure S5. ANRIL regulates the AdiopR1/AMPK/SIRT1 signaling pathway. Table S1. Characteristics of test cohort. (DOCX 4562 kb)
About this article
Cite this article
Sun, LY., Li, XJ., Sun, YM. et al. LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1. Mol Cancer 17, 127 (2018). https://doi.org/10.1186/s12943-018-0879-9
- Glucose metabolism